



Express Mail No. EL 451 600 129 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
MAY 01 2003
TECH CENTER 1600/2900

Application of: Begovich *et al.*

Confirmation No.: 3564

Serial No.: 09/904,420

Art Unit: 1634

Filed: July 12, 2001

Examiner: C. Myers

For: TCF-1 NUCLEOTIDE SEQUENCE
VARIATION

Attorney Docket No: RPA1003
(1803-300-999)

AMENDMENT AND RESPONSE UNDER 37 C.F.R. § 1.116

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Applicants have carefully considered the Office Action mailed February 26, 2003, in connection with the above-captioned patent application. Filed herewith are: 1) Exhibit A ("Marked Up Version of Amended Paragraphs"); 2) Exhibit B (Pending Claims After Entry of the Instant Amendment); and 3) a Fee Transmittal Sheet. This response is being filed within two months from the date of the final Office Action (*see* MPEP § 706.07(f)).

Applicants kindly request reconsideration of the claims in light of the remarks that follow.

IN THE CLAIMS

Please amend the claims as follows:

Please cancel claims 5, 12, 14, 15, 17, and 20-23 without prejudice to renewal.

Please amend claims 18 to read as follows:

18. (Amended) The method of claim 3, wherein said TCF-1 gene comprises SEQ ID NO: 1, an A allele of SEQ ID NO: 1 or the complements thereof.

2.1. to
cancel
(11/10/03)
5-22-03